McKesson (MCK) Projected to Post Earnings on Wednesday

McKesson (NYSE:MCK) is projected to release its Q3 2026 results after the market closes on Wednesday, February 4th. Analysts expect the company to announce earnings of $9.19 per share and revenue of $105.9821 billion for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $9.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.84 by $1.02. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The company had revenue of $103.15 billion during the quarter, compared to the consensus estimate of $103.80 billion. During the same period in the previous year, the company posted $7.07 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. On average, analysts expect McKesson to post $33 EPS for the current fiscal year and $37 EPS for the next fiscal year.

McKesson Trading Up 1.8%

NYSE MCK opened at $846.30 on Tuesday. McKesson has a 12 month low of $570.51 and a 12 month high of $895.58. The stock has a market cap of $104.46 billion, a price-to-earnings ratio of 26.34, a PEG ratio of 1.37 and a beta of 0.40. The company’s 50 day moving average is $827.63 and its two-hundred day moving average is $775.37.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is presently 10.21%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on MCK shares. Wells Fargo & Company upped their target price on shares of McKesson from $816.00 to $914.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Wall Street Zen downgraded McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research lowered McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Jefferies Financial Group lifted their target price on McKesson from $820.00 to $900.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Finally, Barclays started coverage on McKesson in a research note on Monday, December 8th. They issued an “overweight” rating and a $960.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $899.36.

Insider Transactions at McKesson

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $861.63, for a total value of $283,476.27. Following the transaction, the chief accounting officer owned 328 shares of the company’s stock, valued at $282,614.64. This represents a 50.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by insiders.

Institutional Investors Weigh In On McKesson

Several large investors have recently bought and sold shares of MCK. State of Wyoming bought a new position in McKesson during the second quarter valued at $29,000. Turning Point Benefit Group Inc. purchased a new stake in shares of McKesson during the 3rd quarter valued at about $117,000. Osterweis Capital Management Inc. bought a new position in shares of McKesson in the 2nd quarter valued at about $166,000. Triumph Capital Management purchased a new position in McKesson in the third quarter worth about $179,000. Finally, Wealth Watch Advisors INC bought a new stake in McKesson during the third quarter worth approximately $180,000. Institutional investors own 85.07% of the company’s stock.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.